U.K. authorises Moderna’s Omicron specific booster

The U.K. government had, in July, said all adults over 50 would be offered a COVID-19 vaccine booster dose (no vaccine was specified) in the autumn.

August 15, 2022 07:46 pm | Updated August 16, 2022 11:23 am IST - LONDON

Photo used for representation purpose only.

Photo used for representation purpose only. | Photo Credit: Reuters

British health authorities, on August 15, 2022, authorised the use of Moderna’s Omicron variant-specific COVID-19 vaccine booster for adults, the first country to do so. The Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval to Moderna’s bivalent vaccine, Spikevax, which combines mRNA sequences that code for the SARS-CoV-2 spike protein from both the original and the Omicron BA.1 variant.

The U.K. government had, in July, said all adults over 50 would be offered a COVID-19 vaccine booster dose (no vaccine was specified) in the autumn.

The vaccine provided a “strong immune response” against the original strain of the virus as well as the BA.1 strain, MHRA Chief Executive June Raine said in a statement.

Also Read | Booster shots for all U.K. adults

“Like all medicines, the vaccine can cause side effects, although not everybody gets them,” said a patient information sheet on Spikevax, published by the UK government. Included in the possible side effects are an increased risk of myocarditis/pericarditis (inflammation of the heat muscle/ pericardium , the lining around the heart). A few cases of capillary leak syndrome (CLS), i.e., the leakage of fluid from small blood vessels, have also been reported.

“We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this will include the vaccine approved today,” Ms Raine said.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.